MGI Pharma MOGN New patents, anti cancer Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: David Cathcart who wrote (724)	2/21/1998 5:18:00 PM
From: Vector1	Read Replies (3) of 1826

David, I am in MOGN because of Salagen. The drug is now approved for two indications and could easily have in excess of $50m in sales in 3 years at 90%plus gross margins. MGI 114 is a lottery ticket. Numerous compounds have shown great promise in Xenotransplanted tumors in immunosupressed mice only to fail in human clinicals. Cancer is one tough disease. My hope is that the company enters into a collaberation which eliminates the burn and keeps some significant upside. If this happens and Salagen sales grow we will have a double digit stock before the end of the year. V1

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next